CSI Market
Sign In | Register

Eledon Pharmaceuticals Inc (ELDN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ELDN quarterly Cash Flow →
Cash flow data covering Eledon Pharmaceuticals Inc–Dec 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-45.62
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation10.45
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-33.45
Amortization Of Operating Lease Asset-
Warrant Inducement Expense-
Accounts Payable Accrued Expenses And Other Liabilities6.72
Gain Loss On Termination Of Lease-
Operating Lease Right Of Use Asset Amortization Expense-
Non Cash Lease Expense-
Accretion On Investment Discounts-
Income taxes0.01
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.24
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.70
Discontinued operations0.00
Net Cash flow from Operating Activities-62.34
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities171.93
Payments to Acquire Available-for-sale Securities, Debt-161.13
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities10.79
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.23
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Paid For Cancellation Of Common Stock In Connection With Reverse Split-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net53.58
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities53.81
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-62.34
Total Cash Flow2.26
4 historic quarters locked

Sign in to unlock the full Eledon Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Eledon Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-116164

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License